ME02637B - Antitela za receptor 3 faktora rasta epiderma (her3) - Google Patents

Antitela za receptor 3 faktora rasta epiderma (her3)

Info

Publication number
ME02637B
ME02637B MEP-2017-65A MEP6517A ME02637B ME 02637 B ME02637 B ME 02637B ME P6517 A MEP6517 A ME P6517A ME 02637 B ME02637 B ME 02637B
Authority
ME
Montenegro
Prior art keywords
sequence
seq
fragment
her3
antibody
Prior art date
Application number
MEP-2017-65A
Other languages
German (de)
English (en)
French (fr)
Inventor
Winfried Elis
Seth Ettenberg
Andrew Paul Garner
Nicole Haubst
Christian Carsten Silvester Kunz
Sprague Elizabeth Anne Reisinger
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44630597&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ME02637(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ME02637B publication Critical patent/ME02637B/me

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3023—Lung
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3038—Kidney, bladder
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053—Skin, nerves, brain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)

Claims (35)

1.Izolovano antitelo ili njegov fragment koji prepoznaje konformacioni epitop HER3 receptora, naznačeno time što konformacioni epitop uključuje aminokiselinske rezidue 265-277, 315 unutar domena 2 i aminokiselinske rezidue 571, 582-584, 596-597, 600-602, 609-615 unutar domena 4 HER3 receptora, i naznačeno time što antitelo ili njegov fragment blokiraju i ligand-zavisni i ligand-nezavisni prenos signala.
2.Izolovano antitelo ili njegov fragment iz patentnog zahteva 1, naznačeno time što se antitelo ili njegov fragment: a) vezuje za HER3 receptor u neaktivnom stanju; ili b) stabilizuje HER3 receptor u neaktivnom stanju.
3.Izolovano antitelo ili njegov fragment prema patentnom zahtevu 2, naznačeno time što vezivanje antitela stabilizuje HER3 receptor u njegovom neaktivnom stanju, i naznačeno time što HER3 ligand može istovremeno da se veže za ligand-vezujuće mesto na HER3 receptoru.
4.Izolovano antitelo ili njegov fragment iz patentnog zahteva 3, naznačeno time što vezivanje HER3 liganda za ligand-vezujuće mesto ne može da: a) indukuje konformacionu promenu u HER3 receptoru, u aktivno stanje; ili b) aktivira prenos signala.
5. Izolovano antitelo iz patentnog zahteva 1, naznačeno time što: a)se VH antitela ili njegov fragment vezuju za najmanje jednu od sledećih aminokiselinskih HER3 rezidua: Asn266, Lys267, Leu268, Thr269, Gln271, Glu273, Pro274, Asn275, Pro276, His277, Asn315, Asp571, Pro583, His584, Ala596, Lys597; ili b)se VL antitela ili njegov fragment vezuju za najmanje jednu od sledećih aminokiselinskih HER3 rezidua: Tyr265, Lys267, Leu268, Phe270, Gly582, Pro583, Lys597, Ile600, Lys602, Glu609, Arg611, Pro612, Cys613, His614, Glu615.
6. Izolovano antitelo ili njegov fragment iz patentnog zahteva 1, naznačeno time što izolovano antitelo ili njegov fragment prepoznaje konformacioni epitop prvog HER3 receptora, naznačeno time što: a)vezivanje antitela ili njegovog fragmenta za prvi HER3 receptor u odsustvu liganda za HER3 receptor redukuje ligand-nezavisno formiranje proteinskog kompleksa prvi HER3 receptor-drugi HER3 receptor u ćeliji koja ispoljava prvi HER3 receptor i drugi HER3 receptor; ili b)vezivanje antitela ili njegovog fragmenta za prvi HER3 receptor u prisustvu liganda za HER3 redukuje ligand-zavisno formiranje proteinskog kompleksa prvi HER3 receptor-drugi HER3 receptor u ćeliji koja ispoljava prvi HER3 receptor i drugi HER3 receptor.
7. Izolovano antitelo ili njegov fragment iz patentnog zahteva 6, naznačeno time što: a)u odsustvu liganda za HER3 receptor, antitelo ili njegov fragment stabilizuju prvi HER3 receptor u njegovom neaktivnom stanju tako da prvi HER3 receptor ne može da dimerizuje sa drugim HER3 receptorom i formira proteinski kompleks prvi HER3 receptor-drugi HER3 receptor; ili b)u prisustvu liganda za prvi HER3, antitelo ili njegov fragment stabilizuje prvi HER3 receptor u njegovom neaktivnom stanju tako da HER3 receptor ne može da dimerizuje sa drugim HER3 receptorom i formira proteinski kompleks prvi HER3 receptor- drugi HER3 receptor.
8. Izolovano antitelo ili njegov fragment iz patentnog zahteva 7, naznačeno time što nemogućnost formiranja proteinskog kompleksa prvi HER3 receptor-drugi HER3 receptor sprečava aktivaciju prenosa signala.
9. Izolovano antitelo ili njegov fragment iz patentnog zahteva 1, naznačeno time što: a)vezivanje antitela ili njegovog fragmenta za HER3 receptor u odsustvu liganda za HER3 redukuje ligand-nezavisno formiranje proteinskog kompleksa HER2-HER3 u ćeliji koja ispoljava HER2 i HER3; ili b)vezivanje antitela ili njegovog fragmenta za HER3 receptor u prisustvu liganda za HER3 redukuje ligand-zavisno formiranje proteinskog kompleksa HER2-HER3 u ćeliji koja ispoljava HER2 i HER3.
10. Izolovano antitelo ili njegov fragment iz patentnog zahteva 9, naznačeno time što: a) u odsustvu liganda, antitelo ili njegov fragment stabilizuje HER3 receptor u njegovom neaktivnom stanju tako da HER3 receptor ne može da dimerizuje sa HER2 receptorom i formira proteinski kompleks HER2-HER3; ili b) u prisustvu liganda za HER3 antitelo ili njegov fragment stabilizuje HER3 receptor u njegovom neaktivnom stanju tako da HER3 receptor ne može da dimerizuje sa HER2 receptorom i formira proteinski kompleks HER2-HER3.
11. Izolovano antitelo ili njegov fragment iz patentnog zahteva 10, naznačeno time što nemogućnost formiranja proteinskog kompleksa HER2-HER3 sprečava aktivaciju prenosa signala.
12. Izolovano antitelo ili njegov fragment iz patentnog zahteva 1, naznačeno time što je antitelo izabrano iz grupe koju sačinjavaju monoklonsko antitelo, poliklonsko antitelo, himerno antitelo, humanizovano antitelo i sintetisano antitelo.
13. Izolovano antitelo ili njegov fragment iz patentnih zahteva 3, 6 ili 9, naznačeno time što je ligand za HER3 izabran iz grupe koju sačinjavaju neuregulin 1 (NRG), neuregulin 2, betacelulin, heparin-vezujući faktor rasta epiderma, i epiregulin.
14. Izolovano antitelo ili njegov fragment iz patentnog zahteva 1, naznačeno time što antitelo ili njegov fragment inhibira fosforilaciju HER3 kao što je procenjeno primenom:a) eseja fosforilacije nezavisnog od HER3 liganda ilib) eseja fosforilacije zavisnog od HER3 liganda.
15. Izolovano antitelo ili njegov fragment iz patentnog zahteva 14, naznačeno time što:a) test HER3-ligand nezavisne fosforilacije, koristi HER2 amplifikovane ćelije, gde su HER2 amplifikovane ćelije SK-Br-3 ćelije ib) test HER3-ligand zavisne fosforilacije, koristi stimulisane MCF7 ćelije u prisustvu neuregulina (NRG).
16. Izolovano antitelo ili njegov fragment iz patentnog zahteva 1, naznačeno time što je antitelo ili njegov fragment u unakrsnoj kompeticiji sa ili se vezuje za isti konformacioni epitop kao antitelo MOR9823; MOR9824; MOR9825; MOR9974; MOR10452; MOR10701; MOR10702; MOR10703; MOR10703 N52S; MOR10703 N52G; MOR10703 N52S_S52aN; MOR10703 A50V_N52S; MOR10703 A50V_N52G; MOR10703 S52aT; MOR10701 R55S; MOR10701R55G; MOR10701 R55K; MOR10701 delS56; MOR12609 ili MOR12610.
17. Izolovano antitelo ili njegov fragment iz bilo kog od gore navedenih patentnih zahteva, naznačeno time što je antitelo izabrano iz grupe koju sačinjavaju monoklonsko antitelo, himerno antitelo, jednolančano antitelo, Fab fragment i scFv.
18. Izolovano antitelo ili njegov fragment iz bilo kog od gore navedenih patentnih zahteva, naznačeno time što je antitelo humano.
19. Izolovano antitelo ili njegov fragment iz bilo kog od gore navedenih patentnih zahteva, naznačeno time što u sastav antitela ulazi konstantni region humanog teškog lanca i konstantni region humanog lakog lanca.
20. Izolovano antitelo ili njegov fragment iz bilo kog od gore navedenih patentnih zahteva, naznačeno time što se antitelo ili njegov fragment vezuju i za HER3 čoveka i za HER3 majmuna cynomologus.
21. Izolovano antitelo ili njegov fragment iz bilo kog od gore navedenih patentnih zahteva, naznačeno time što je antitelo ili njegov fragment IgG izotipa.
22. Izolovano antitelo ili njegov fragment iz bilo kog od gore navedenih patentnih zahteva, naznačeno time što antitelo sadrži okvirne sekvence (framework) nastale zamenom aminokiselinama iz odgovarajućih germinativnih sekvenci humanih regiona VH ili VL.
23. Izolovano antitelo ili njegov fragment iz patentnog zahteva 1, u čiji sastav prema računici Kabat ili Chothia ulazi 6 regiona CDR bilo kog od sledećih antitela MOR9823; MOR9824; MOR9825; MOR9974; MOR10452; MOR10701; MOR10702; MOR10703; MOR10703 N52S; MOR10703 N52G; MOR10703 N52S_S52aN; MOR10703 A50V_N52S; MOR10703 A50V_N52G; MOR10703 S52aT; MOR10701 R55S; MOR10701R55G; MOR10701 R55K; MOR10701 delS56; MOR12609 ili MOR12610.
24. U sastav izolovanog antitela ili njegovog fragmenta iz patentnog zahteva 1, ulazi:a) VH koji sadrži sekvencu SEQ ID NO: 15 i VL koji sadrži sekvencu SEQ ID NO: 14, ili aminokiselinsku sekvencu koja im je 97-99% identična; ilib) VH koji sadrži sekvencu SEQ ID NO: 33 i VL koji sadrži sekvencu SEQ ID NO: 32, ili aminokiselinsku sekvencu koja im je 97-99% identična; ilic) VH koji sadrži sekvencu SEQ ID NO: 51 i VL koji sadrži sekvencu SEQ ID NO: 50, ili aminokiselinsku sekvencu koja im je 97-99% identična; ilid) VH koji sadrži sekvencu SEQ ID NO: 69 i VL koji sadrži sekvencu SEQ ID NO: 68, ili aminokiselinsku sekvencu koja im je 97-99% identična; ilie) VH koji sadrži sekvencu SEQ ID NO: 87 i VL koji sadrži sekvencu SEQ ID NO: 86, ili aminokiselinsku sekvencu koja im je 97-99% identična; ilif) VH koji sadrži sekvencu SEQ ID NO: 105 i VL koji sadrži sekvencu SEQ ID NO: 104, ili aminokiselinsku sekvencu koja im je 97-99% identična; ilig) VH koji sadrži sekvencu SEQ ID NO: 123 i VL koji sadrži sekvencu SEQ ID NO: 122, ili aminokiselinsku sekvencu koja im je 97-99% identična; ilih) VH koji sadrži sekvencu SEQ ID NO: 141 i VL koji sadrži sekvencu SEQ ID NO: 140, ili aminokiselinsku sekvencu koja im je 97-99% identična; ilii) VH koji sadrži sekvencu SEQ ID NO: 159 i VL koji sadrži sekvencu SEQ ID NO: 158, ili aminokiselinsku sekvencu koja im je 97-99% identična; ilij) VH koji sadrži sekvencu SEQ ID NO: 177 i VL koji sadrži sekvencu SEQ ID NO: 176, ili aminokiselinsku sekvencu koja im je 97-99% identična; ilik) VH koji sadrži sekvencu SEQ ID NO: 195 i VL koji sadrži sekvencu SEQ ID NO: 194, ili aminokiselinsku sekvencu koja im je 97-99% identična; ilil) VH koji sadrži sekvencu SEQ ID NO: 213 i VL koji sadrži sekvencu SEQ ID NO: 212, ili aminokiselinsku sekvencu koja im je 97-99% identična; ilim) VH koji sadrži sekvencu SEQ ID NO: 231 i VL koji sadrži sekvencu SEQ ID NO: 230, ili aminokiselinsku sekvencu koja im je 97-99% identična; ilin) VH koji sadrži sekvencu SEQ ID NO: 249 i VL koji sadrži sekvencu SEQ ID NO: 248, ili aminokiselinsku sekvencu koja im je 97-99% identična; ilio) VH koji sadrži sekvencu SEQ ID NO: 267 i VL koji sadrži sekvencu SEQ ID NO: 266, ili aminokiselinsku sekvencu koja im je 97-99% identična; ilip) VH koji sadrži sekvencu SEQ ID NO: 285 i VL koji sadrži sekvencu SEQ ID NO: 284, ili aminokiselinsku sekvencu koja im je 97-99% identična; iliq) VH koji sadrži sekvencu SEQ ID NO: 303 i VL koji sadrži sekvencu SEQ ID NO: 302, ili aminokiselinsku sekvencu koja im je 97-99% identična; ilir) VH koji sadrži sekvencu SEQ ID NO: 321 i VL koji sadrži sekvencu SEQ ID NO: 320, ili aminokiselinsku sekvencu koja im je 97-99% identična; ilis) VH koji sadrži sekvencu SEQ ID NO: 339 i VL koji sadrži sekvencu SEQ ID NO: 338, ili aminokiselinsku sekvencu koja im je 97-99% identična; ilit) VH koji sadrži sekvencu SEQ ID NO: 357 i VL koji sadrži sekvencu SEQ ID NO: 356, ili aminokiselinsku sekvencu koja im je 97-99% identična; iliu) VH koji sadrži sekvencu SEQ ID NO: 375 i VL koji sadrži sekvencu SEQ ID NO: 374, ili aminokiselinsku sekvencu koja im je 97-99% identična.
25. Izolovano antitelo ili njegov fragment iz patentnog zahteva 1, sadrži sekvencu varijabilnog domena teškog lanca koja poseduje SEQ ID NO: 493 i/ili sekvencu varijabilnog domena lakog lanca koja poseduje SEQ ID NO: 494.
26. Izolovano antitelo ili njegov fragment iz patentnog zahteva 1, sadrži;a) CDR1 varijabilnog regiona teškog lanca sa sekvencom SEQ ID NO: 2; CDR2 sa sekvencom SEQ ID NO: 3; CDR3 sa sekvencom SEQ ID NO: 4; CDR1 varijabilnog regiona lakog lanca sa sekvencom SEQ ID NO: 5; CDR2 sa sekvencom SEQ ID NO: 6; i CDR3 sa sekvencom SEQ ID NO: 7; ilib) CDR1 varijabilnog regiona teškog lanca sa sekvencom SEQ ID NO: 20; CDR2 sa sekvencom SEQ ID NO: 21; CDR3 sa sekvencom SEQ ID NO: 22; CDR1 varijabilnog regiona lakog lanca sa sekvencom SEQ ID NO: 23; CDR2 sa sekvencom SEQ ID NO: 24; i CDR3 sa sekvencom SEQ ID NO: 25; ilic) CDR1 varijabilnog regiona teškog lanca sa sekvencom SEQ ID NO: 38; CDR2 sa sekvencom SEQ ID NO: 39; CDR3 sa sekvencom SEQ ID NO: 40; CDR1 varijabilnog regiona lakog lanca sa sekvencom SEQ ID NO: 41; CDR2 sa sekvencom SEQ ID NO: 42; i CDR3 sa sekvencom SEQ ID NO: 43; ilid) CDR1 varijabilnog regiona teškog lanca sa sekvencom SEQ ID NO: 56; CDR2 sa sekvencom SEQ ID NO: 57; CDR3 sa sekvencom SEQ ID NO: 58; CDR1 varijabilnog regiona lakog lanca sa sekvencom SEQ ID NO: 59; CDR2 sa sekvencom SEQ ID NO: 60; i CDR3 sa sekvencom SEQ ID NO: 61; ilie) CDR1 varijabilnog regiona teškog lanca sa sekvencom SEQ ID NO: 74; CDR2 sa sekvencom SEQ ID NO: 75; CDR3 sa sekvencom SEQ ID NO: 76; CDR1 varijabilnog regiona lakog lanca sa sekvencom SEQ ID NO: 77; CDR2 sa sekvencom SEQ ID NO: 78; i CDR3 of SEQ ID NO: 79; ilif) CDR1 varijabilnog regiona teškog lanca sa sekvencom SEQ ID NO: 92; CDR2 sa sekvencom SEQ ID NO: 93; CDR3 sa sekvencom SEQ ID NO: 94; CDR1 varijabilnog regiona lakog lanca sa sekvencom SEQ ID NO: 95; CDR2 sa sekvencom SEQ ID NO: 96; i CDR3 of SEQ ID NO: 97; ilig) CDR1 varijabilnog regiona teškog lanca sa sekvencom SEQ ID NO: 110; CDR2 sa sekvencom SEQ ID NO: 111; CDR3 sa sekvencom SEQ ID NO: 112; CDR1 varijabilnog regiona lakog lanca sa sekvencom SEQ ID NO: 113; CDR2 sa sekvencom SEQ ID NO: 114; i CDR3 sa sekvencom SEQ ID NO: 115; ilih) CDR1 varijabilnog regiona teškog lanca sa sekvencom SEQ ID NO: 128; CDR2 sa sekvencom SEQ ID NO: 129; CDR3 sa sekvencom SEQ ID NO: 130; CDR1 varijabilnog regiona lakog lanca sa sekvencom SEQ ID NO: 131; CDR2 sa sekvencom SEQ ID NO: 132; i CDR3 sa sekvencom SEQ ID NO: 133; ilii) CDR1 varijabilnog regiona teškog lanca sa sekvencom SEQ ID NO: 146; CDR2 sa sekvencom SEQ ID NO: 147; CDR3 sa sekvencom SEQ ID NO: 148; CDR1 varijabilnog regiona lakog lanca sa sekvencom SEQ ID NO: 149; CDR2 sa sekvencom SEQ ID NO: 150; i CDR3 sa sekvencom SEQ ID NO: 151; ilij) CDR1 varijabilnog regiona teškog lanca sa sekvencom SEQ ID NO: 164; CDR2 sa sekvencom SEQ ID NO: 165; CDR3 sa sekvencom SEQ ID NO: 166; CDR1 varijabilnog regiona lakog lanca sa sekvencom SEQ ID NO: 167; CDR2 sa sekvencom SEQ ID NO: 168; i CDR3 of SEQ ID NO: 169; ilik) CDR1 varijabilnog regiona teškog lanca sa sekvencom SEQ ID NO: 182; CDR2 sa sekvencom SEQ ID NO: 183; CDR3 sa sekvencom SEQ ID NO: 184; CDR1 varijabilnog regiona lakog lanca sa sekvencom SEQ ID NO: 185; CDR2 sa sekvencom SEQ ID NO: 186; i CDR3 sa sekvencom SEQ ID NO: 187; ilil) CDR1 varijabilnog regiona teškog lanca sa sekvencom SEQ ID NO: 200; CDR2 sa sekvencom SEQ ID NO: 201; CDR3 sa sekvencom SEQ ID NO: 202; CDR1 varijabilnog regiona lakog lanca sa sekvencom SEQ ID NO: 203; CDR2 sa sekvencom SEQ ID NO: 204; i CDR3 sa sekvencom SEQ ID NO: 205; ilim) CDR1 varijabilnog regiona teškog lanca sa sekvencom SEQ ID NO: 218; CDR2 sa sekvencom SEQ ID NO: 219; CDR3 sa sekvencom SEQ ID NO: 220; CDR1 varijabilnog regiona lakog lanca sa sekvencom SEQ ID NO: 221; CDR2 sa sekvencom of SEQ ID NO: 222; i CDR3 sa sekvencom SEQ ID NO: 223; ilin) CDR1 varijabilnog regiona teškog lanca sa sekvencom SEQ ID NO: 236; CDR2 sa sekvencom SEQ ID NO: 237; CDR3 sa sekvencom of SEQ ID NO: 238; CDR1 varijabilnog regiona lakog lanca sa sekvencom SEQ ID NO: 239; CDR2 sa sekvencom SEQ ID NO: 240; i CDR3 sa sekvencom SEQ ID NO: 241; ilio) CDR1 varijabilnog regiona teškog lanca sa sekvencom SEQ ID NO: 254; CDR2 sa sekvencom SEQ ID NO: 255; CDR3 sa sekvencom SEQ ID NO: 256; CDR1 varijabilnog regiona lakog lanca sa sekvencom SEQ ID NO: 257; CDR2 sa sekvencom SEQ ID NO: 258; i CDR3 sa sekvencom SEQ ID NO: 259; ilip) CDR1 varijabilnog regiona teškog lanca sa sekvencom SEQ ID NO: 272; CDR2 sa sekvencom SEQ ID NO: 273; CDR3 sa sekvencom SEQ ID NO: 274; CDR1 varijabilnog regiona lakog lanca sa sekvencom SEQ ID NO: 275; CDR2 sa sekvencom SEQ ID NO: 276; i CDR3 sa sekvencom SEQ ID NO: 277; iliq) CDR1 varijabilnog regiona teškog lanca sa sekvencom SEQ ID NO: 290; CDR2 sa sekvencom SEQ ID NO: 291; CDR3 sa sekvencom SEQ ID NO: 292; CDR1 varijabilnog regiona lakog lanca sa sekvencom SEQ ID NO: 293; CDR2 sa sekvencom SEQ ID NO: 294; i CDR3 sa sekvencom SEQ ID NO: 295; ilir) CDR1 varijabilnog regiona teškog lanca sa sekvencom SEQ ID NO: 308; CDR2 sa sekvencom SEQ ID NO: 309; CDR3 sa sekvencom SEQ ID NO: 310; CDR1 varijabilnog regiona lakog lanca sa sekvencom SEQ ID NO: 311; CDR2 sa sekvencom SEQ ID NO: 312; i CDR3 sa sekvencom SEQ ID NO: 313; ilis) CDR1 varijabilnog regiona teškog lanca sa sekvencom SEQ ID NO: 326; CDR2 sa sekvencom SEQ ID NO: 327; CDR3 sa sekvencom SEQ ID NO: 328; CDR1 varijabilnog regiona lakog lanca sa sekvencom SEQ ID NO: 329; CDR2 sa sekvencom SEQ ID NO: 330; i CDR3 sa sekvencom SEQ ID NO: 331; ilit) CDR1 varijabilnog regiona teškog lanca sa sekvencom SEQ ID NO: 344; CDR2 sa sekvencom SEQ ID NO: 345; CDR3 sa sekvencom SEQ ID NO: 346; CDR1 varijabilnog regiona lakog lanca sa sekvencom SEQ ID NO: 347; CDR2 sa sekvencom SEQ ID NO: 348; i CDR3 sa sekvencom SEQ ID NO: 349; iliu) CDR1 varijabilnog regiona teškog lanca sa sekvencom SEQ ID NO: 362; CDR2 sa sekvencom SEQ ID NO: 363; CDR3 sa sekvencom SEQ ID NO: 364; CDR1 varijabilnog regiona lakog lanca sa sekvencom SEQ ID NO: 365; CDR2 sa sekvencom SEQ ID NO: 366; i CDR3 sa sekvencom SEQ ID NO: 367.
27. Fragment antitela iz bilo kog prethodnog patentnog zahteva, izabran je iz grupe koja se sastoji od; Fab, F(ab2)’, F(ab)2’, scFv, VHH, VH, VL, d antitela .
28. Farmaceutska kompozicija se sastoji od antitela ili njegovog fragmenta izabranog iz bilo kog od prethodnih patentnih zahteva i farmaceutski prihvatljivog nosača.
29. Farmaceutska kompozicija iz patentnog zahteva 28, osim toga sadrži dodatni terapijski agens.
30. Farmaceutska kompozicija iz patentnog zahteva 29, naznačeno time što je dodatni terapijski agens izabran iz grupe koja sadrži inhibitor HER1, inhibitor HER2, inhibitor HER3, inhibitor HER4, inhibitor mTOR i inhibitor PI3 kinaze.
31. Farmaceutska kompozicija iz patentnog zahteva 30, naznačeno time što je:a) kada je dodatni terapijski agens inhibitor HER1, inhibitor HER1 je izabran iz grupe u čiji sastav ulaze Matuzumab (EMD72000), Erbitux®/Cetuximab, Vectibix® /Panitumumab, monoklonskog antitela 806, Nimotuzumab, Iressa® /Gefitinib, CI-1033 (PD183805), Lapatinib (GW-572016), Tykerb® /Lapatinib Ditosylate, Tarceva® / Erlotinib HCL (OSI-774), PKI-166, i Tovok®; inhibitor HER2 je izabran iz grupe u čiji sastav ulaze Pertuzumab, Trastuzumab, MM-111, neratinib, lapatinib ili lapatinib ditosylate /Tykerb®; inhibitor HER3 je izabran iz grupe u čiji sastav ulaze MM-121, MM-111, IB4C3, 2DID12 (U3 Pharma AG), AMG888 (Amgen), AV-203(Aveo), MEHD7945A (Genentech) i mali molekuli koji inhibiraju HER3; i inhibitor HER4;b) kada je dodatni terapijski agens inhibitor mTOR, inhibitor mTOR je izabran iz grupe u čiji sastav ulaze Temsirolimus/Torisel®, ridaforolimus / Deforolimus, AP23573, MK8669, everolimus /Affinitor® ;c) kada je dodatni terapijski agens inhibitor PI3 kinaze, inhibitor PI3 kinaze je izabran iz grupe u čiji sastav ulaze GDC 0941, BEZ235, BMK120 i BYL719.
32. Antitelo ili njegov fragment prema bilo kom od patentnih zahteva od 1 do 27 ili kompozicija prema bilo kom od patentnih zahteva od 28 do 31 za upotrebu u svojstvu leka.
33. Antitelo ili njegov fragment prema bilo kom od patentnih zahteva od 1 do 27 ili kompozicija prema bilo kom od patentnih zahteva od 28 do 31 za upotrebu u lečenju kancera.
34. Antitelo ili njegov fragment prema bilo kom od patentnih zahteva od 1 do 27 ili kompozicija prema bilo kom od patentnih zahteva od 28 do 31 za upotrebu u lečenju kancera prema patentnom zahtevu 33, naznačeno time što je kancer posredovan HER3 signalnim putem.
35. Antitelo ili njegov fragment prema bilo kom od patentnih zahteva od 1 do 27 ili kompozicija prema bilo kom od patentnih zahteva od 28 do 31 za upotrebu u lečenju kancera prema patentnom zahtevu 34, naznačeno time što je kancer izabran iz grupe u kojoj se nalaze kancer dojke, kolorektalni kancer, kancer pluća, multipli mijelom, kancer jajnika, kancer jetre, kancer želuca, kancer pankreasa, kancer prostate, akutna mijeloidna leukemija, hronična mijeloidna leukemija, osteosarkom, karcinom skvamoznih ćelija, tumori ovojnice perifernog nerva, švanom, kancer glave i vrata, kancer mokraćne bešike, kancer jednjaka, glioblastom, sarkom svetlih ćelija mekog tkiva, maligni mezoteliom, neurofibromatoza, kancer bubrega, i melanom.
MEP-2017-65A 2010-08-20 2011-08-22 Antitela za receptor 3 faktora rasta epiderma (her3) ME02637B (me)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37540810P 2010-08-20 2010-08-20
EP11746252.3A EP2606070B1 (en) 2010-08-20 2011-08-22 Antibodies for epidermal growth factor receptor 3 (her3)
PCT/EP2011/064407 WO2012022814A1 (en) 2010-08-20 2011-08-22 Antibodies for epidermal growth factor receptor 3 (her3)

Publications (1)

Publication Number Publication Date
ME02637B true ME02637B (me) 2017-06-20

Family

ID=44630597

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2017-65A ME02637B (me) 2010-08-20 2011-08-22 Antitela za receptor 3 faktora rasta epiderma (her3)

Country Status (39)

Country Link
US (3) US8735551B2 (me)
EP (1) EP2606070B1 (me)
JP (4) JP6057896B2 (me)
KR (1) KR102027011B1 (me)
CN (2) CN105037552B (me)
AU (1) AU2011290672B2 (me)
BR (1) BR112013004012B1 (me)
CA (1) CA2806637C (me)
CL (2) CL2013000459A1 (me)
CO (1) CO6680688A2 (me)
CR (1) CR20130071A (me)
CU (1) CU24094B1 (me)
CY (1) CY1118761T1 (me)
DK (1) DK2606070T3 (me)
DO (1) DOP2013000044A (me)
EA (1) EA036314B1 (me)
ES (1) ES2620255T3 (me)
GE (1) GEP201706605B (me)
GT (1) GT201300046A (me)
HR (1) HRP20170462T1 (me)
HU (1) HUE031855T2 (me)
IL (2) IL226712B (me)
LT (1) LT2606070T (me)
MA (1) MA34524B1 (me)
ME (1) ME02637B (me)
MX (1) MX2013002046A (me)
MY (1) MY162825A (me)
NI (1) NI201300023A (me)
NZ (1) NZ607337A (me)
PE (1) PE20140230A1 (me)
PH (1) PH12013500333A1 (me)
PL (1) PL2606070T3 (me)
PT (1) PT2606070T (me)
RS (1) RS55930B1 (me)
SG (1) SG187908A1 (me)
SI (1) SI2606070T1 (me)
SM (1) SMT201700217T1 (me)
UA (1) UA114883C2 (me)
WO (1) WO2012022814A1 (me)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20160737T1 (hr) 2009-12-22 2016-07-15 Roche Glycart Ag Anti-her3-protutijela i njihove uporabe
PH12013500333A1 (en) * 2010-08-20 2013-04-22 Novartis Ag Antibodies for epidermal growth factor receptor 3 (her3)
EP2635605B1 (en) * 2010-11-01 2018-07-25 Symphogen A/S Anti-her3 antibodies and compositions
ITRM20100577A1 (it) * 2010-11-02 2012-05-03 Takis Srl Immunoterapia contro il recettore erbb-3
DK2699602T3 (en) * 2011-04-19 2017-06-06 Merrimack Pharmaceuticals Inc BISPECIFIC ANTI-IGF-1R AND ANTI-ERBB3 ANTIBODIES
JPWO2012176779A1 (ja) * 2011-06-20 2015-02-23 協和発酵キリン株式会社 抗ｅｒｂＢ３抗体
US9273143B2 (en) 2011-09-30 2016-03-01 Regeneron Pharmaceuticals, Inc. Methods and compositions comprising a combination of an anti-ErbB3 antibody and an anti-EGFR antibody
MX357391B (es) 2011-09-30 2018-07-06 Regeneron Pharma Anticuerpos anti-erbb3 y usos de los mismos.
GB2504139B (en) * 2012-07-20 2014-12-31 Argen X Bv Antibodies to highly conserved targets produced by the immunisation of Camelidae species
AU2012335543C1 (en) * 2011-11-09 2017-12-14 Beijing Cotimes Biotech Co., Ltd., HER3 antibodies and uses thereof
US9220775B2 (en) 2011-11-23 2015-12-29 Medimmune Llc Binding molecules specific for HER3 and uses thereof
TW201328706A (zh) * 2011-12-05 2013-07-16 Novartis Ag 表皮生長因子受體３（ｈｅｒ３）之抗體
US20130273029A1 (en) * 2011-12-05 2013-10-17 Novartis Ag Antibodies for epidermal growth factor receptor 3 (her3) directed to domain ii of her3
US20150037336A1 (en) * 2012-02-22 2015-02-05 U3 Pharma Gmbh Combination of hb-egf binding protein and egfr inhibitor
AU2013305887B2 (en) * 2012-08-21 2018-02-22 Saladax Biomedical Inc. Antibodies to risperidone and use thereof
US9346890B2 (en) * 2012-10-25 2016-05-24 Sorrento Therapeutics, Inc. Antigen binding proteins that bind ErbB3
SG11201502534UA (en) * 2012-11-08 2015-05-28 Hoffmann La Roche Anti-her3/her4 antigen binding proteins binding to the beta-hairpin of her3 and the beta-hairpin of her4
MX2015005757A (es) 2012-11-08 2015-11-18 Hoffmann La Roche Proteinas ligantes de antigeno her3 de union a la horquilla beta de her3.
CN102993305B (zh) * 2012-11-16 2015-05-13 上海赛伦生物技术有限公司 人源抗人表皮生长因子受体抗体及其编码基因与应用
AR094403A1 (es) 2013-01-11 2015-07-29 Hoffmann La Roche Terapia de combinación de anticuerpos anti-her3
EP3046468A4 (en) * 2013-09-18 2017-06-21 Sloan-kettering Institute For Cancer Research Methods and compositions for imaging disorders using polyspecific agents
WO2015048008A2 (en) 2013-09-24 2015-04-02 Medimmune, Llc Binding molecules specific for her3 and uses thereof
US10570204B2 (en) 2013-09-26 2020-02-25 The Medical College Of Wisconsin, Inc. Methods for treating hematologic cancers
WO2015066543A1 (en) * 2013-11-01 2015-05-07 Board Of Regents, The University Of Texas System Targeting her2 and her3 with bispecific antibodies in cancerous cells
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
IL301147A (en) 2014-02-28 2023-05-01 Merus Nv An antibody that binds to ErbB-2 and ErbB-3
EP3110846B1 (en) 2014-02-28 2020-08-19 Merus N.V. Antibodies that bind egfr and erbb3
EP3660050A1 (en) 2014-03-14 2020-06-03 Novartis AG Antibody molecules to lag-3 and uses thereof
US10745490B2 (en) 2014-04-11 2020-08-18 Celldex Therapeutics, Inc. Anti-ErbB antibodies and methods of use thereof
FR3020063A1 (fr) 2014-04-16 2015-10-23 Gamamabs Pharma Anticorps humain anti-her4
CN106255705B (zh) * 2014-05-14 2021-01-08 豪夫迈·罗氏有限公司 结合HER3β-发夹和HER2域II的HER3/HER2双特异性抗体
RU2016148682A (ru) * 2014-05-14 2018-06-19 Ф. Хоффманн-Ля Рош Аг Антитела против рецептора-3 к эпидермальному ростовому фактору человека (her3), связывающиеся с бета-шпилькой her3
WO2016011167A1 (en) 2014-07-16 2016-01-21 Dana-Farber Cancer Institute, Inc., Et Al Her3 inhibition in low-grade serous ovarian cancers
CN105367657B (zh) * 2014-08-14 2019-09-13 上海生物制品研究所有限责任公司 抗her3抗体、其制法及其应用
KR20170060042A (ko) 2014-09-13 2017-05-31 노파르티스 아게 Alk 억제제의 조합 요법
US20170209574A1 (en) 2014-10-03 2017-07-27 Novartis Ag Combination therapies
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
CN114920840A (zh) 2014-10-14 2022-08-19 诺华股份有限公司 针对pd-l1的抗体分子及其用途
JP6847835B2 (ja) * 2014-12-12 2021-03-24 ザ ジェネラル ホスピタル コーポレイション 乳がん脳転移の処置
JO3746B1 (ar) 2015-03-10 2021-01-31 Aduro Biotech Inc تركيبات وطرق لتنشيط الإشارات المعتمدة على "منبه أو تحفيز جين انترفيرون"
CA2991799A1 (en) * 2015-07-15 2017-01-19 Zymeworks Inc. Drug-conjugated bi-specific antigen-binding constructs
TW201716439A (zh) 2015-07-20 2017-05-16 美國禮來大藥廠 Ｈｅｒ３抗體
PL3317301T3 (pl) 2015-07-29 2021-11-15 Novartis Ag Terapie skojarzone zawierające cząsteczki przeciwciał przeciw lag-3
EP3316902A1 (en) 2015-07-29 2018-05-09 Novartis AG Combination therapies comprising antibody molecules to tim-3
US20180222982A1 (en) 2015-07-29 2018-08-09 Novartis Ag Combination therapies comprising antibody molecules to pd-1
WO2017030909A1 (en) 2015-08-14 2017-02-23 Allergan, Inc. Heavy chain only antibodies to pdgf
HUE055222T2 (hu) 2015-10-23 2021-11-29 Merus Nv Megkötõ molekulák, amelyek gátolják a rák növekedését
MY198562A (en) 2015-11-03 2023-09-05 Janssen Biotech Inc Antibodies specifically binding pd-1 and their uses
JP6629581B2 (ja) * 2015-11-30 2020-01-15 サントリーホールディングス株式会社 ヒドロキシチロソール含有茶飲料
TWI726942B (zh) 2015-11-30 2021-05-11 美商輝瑞股份有限公司 位點專一性ｈｅｒ２抗體藥物共軛體
KR101746152B1 (ko) * 2015-12-07 2017-06-13 주식회사 이수앱지스 ＥｒｂＢ3에 특이적으로 결합하는 항체 및 그의 용도
JP2018536682A (ja) 2015-12-11 2018-12-13 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｅｇｆｒ及び／またはｅｒｂｂ３遮断に耐性のある腫瘍の成長を低減または防止するための方法
JP2019503349A (ja) 2015-12-17 2019-02-07 ノバルティス アーゲー Ｐｄ−１に対する抗体分子およびその使用
CN109310754A (zh) 2016-03-15 2019-02-05 梅里麦克制药股份有限公司 使用包含抗erbb3抗体的联合疗法治疗er+、her2-、hrg+乳腺癌的方法
EP3507367A4 (en) 2016-07-05 2020-03-25 Aduro BioTech, Inc. CYCLIC DINUCLEOTID COMPOUNDS WITH INCLUDED NUCLEIC ACIDS AND USES THEREOF
CN117982673A (zh) 2017-02-28 2024-05-07 第一三共株式会社 抗her3抗体-药物偶联物的应用
CN110650752A (zh) 2017-03-31 2020-01-03 美勒斯公司 用于治疗具有NRG1融合基因的细胞的ErbB-2和ErbB3结合双特异性抗体
JP7304815B2 (ja) 2017-03-31 2023-07-07 メルス ナムローゼ フェンノートシャップ Ｅｒｂｂ－２、ｅｒｂｂ－２／ｅｒｂｂ－３陽性腫瘍を有する個体の処置のための、ｅｒｂ－２及びｅｒｂｂ－３の細胞外部分上のエピトープに結合する抗原結合部位を含むｅｒｂｂ－２標的化剤及び二重特異性抗体
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
EA201992522A1 (ru) 2017-05-17 2020-04-22 Мерус Н.В. КОМБИНАЦИЯ БИСПЕЦИФИЧЕСКОГО АНТИТЕЛА К ErbB-2/ErbB-3 С ЭНДОКРИННОЙ ТЕРАПИЕЙ РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ
EP3642240A1 (en) 2017-06-22 2020-04-29 Novartis AG Antibody molecules to cd73 and uses thereof
EP3665198B9 (en) 2017-08-09 2025-05-21 Merus N.V. Antibodies that bind egfr and cmet
CA3073919A1 (en) 2017-08-30 2019-03-07 Beijing Xuanyi Pharmasciences Co., Ltd. Cyclic di-nucleotides as stimulator of interferon genes modulators
JP7378394B2 (ja) 2017-11-03 2023-11-13 オーリジーン オンコロジー リミテッド Ｔｉｍ－３およびｐｄ－１経路の二重阻害剤
WO2019087092A1 (en) 2017-11-06 2019-05-09 Aurigene Discovery Technologies Limited Conjoint therapies for immunomodulation
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies
CN111836621A (zh) 2018-03-14 2020-10-27 奥瑞基尼探索技术有限公司 使用1,2,4-噁二唑化合物调节tigit和pd-1信号传导途径的方法
WO2019185164A1 (en) 2018-03-29 2019-10-03 Hummingbird Bioscience Holdings Pte. Ltd. Her3 antigen-binding molecules
TWI869346B (zh) 2018-05-30 2025-01-11 瑞士商諾華公司 Ｅｎｔｐｄ２抗體、組合療法、及使用該等抗體和組合療法之方法
EP3849538A4 (en) 2018-09-10 2022-06-29 Mirati Therapeutics, Inc. Combination therapies
TW202024133A (zh) 2018-09-20 2020-07-01 日商第一三共股份有限公司 利用投予抗her3抗體-藥物結合物之her3突變癌之治療
CN110760003A (zh) * 2019-09-10 2020-02-07 广东药科大学 一种抗her3单链抗体的制备方法
CN114502590A (zh) 2019-09-18 2022-05-13 诺华股份有限公司 Entpd2抗体、组合疗法、以及使用这些抗体和组合疗法的方法
AU2021275117A1 (en) * 2020-05-19 2022-12-01 Momenta Pharmaceuticals, Inc. Preparation and purification of hypersialylated IgG
US20240293565A1 (en) * 2021-06-15 2024-09-05 Beijing Sinotau Bio-Pharmaceuticals Technology Co., Ltd. Anti-her3 antibody, antibody drug conjugate containing the same, and use thereof
CN113788895B (zh) * 2021-10-14 2023-09-15 陕西健吉跃生物科技有限公司 一种兔多克隆抗体及其制备方法和应用

Family Cites Families (185)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
DE3378250D1 (en) 1982-04-22 1988-11-24 Ici Plc Continuous release formulations
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4708871A (en) 1983-03-08 1987-11-24 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
US5128326A (en) 1984-12-06 1992-07-07 Biomatrix, Inc. Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4881175A (en) 1986-09-02 1989-11-14 Genex Corporation Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
US5013653A (en) 1987-03-20 1991-05-07 Creative Biomolecules, Inc. Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
JPH02500329A (ja) 1987-05-21 1990-02-08 クリエイテイブ・バイオマリキユールズ・インコーポレーテツド ターゲット化多機能蛋白質
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US4880078A (en) 1987-06-29 1989-11-14 Honda Giken Kogyo Kabushiki Kaisha Exhaust muffler
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
US5336603A (en) 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
US5476996A (en) 1988-06-14 1995-12-19 Lidak Pharmaceuticals Human immune system in non-human animal
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
KR900005995A (ko) 1988-10-31 1990-05-07 우메모또 요시마사 변형 인터류킨-2 및 그의 제조방법
ATE102631T1 (de) 1988-11-11 1994-03-15 Medical Res Council Klonierung von immunglobulin sequenzen aus den variabelen domaenen.
JP2989002B2 (ja) 1988-12-22 1999-12-13 キリン―アムジエン・インコーポレーテツド 化学修飾顆粒球コロニー刺激因子
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
ATE92107T1 (de) 1989-04-29 1993-08-15 Delta Biotechnology Ltd N-terminale fragmente von menschliches serumalbumin enthaltenden fusionsproteinen.
US6291158B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
US5112946A (en) 1989-07-06 1992-05-12 Repligen Corporation Modified pf4 compositions and methods of use
FR2650598B1 (fr) 1989-08-03 1994-06-03 Rhone Poulenc Sante Derives de l'albumine a fonction therapeutique
AU6430190A (en) 1989-10-10 1991-05-16 Pitman-Moore, Inc. Sustained release composition for macromolecular proteins
WO1991006570A1 (en) 1989-10-25 1991-05-16 The University Of Melbourne HYBRID Fc RECEPTOR MOLECULES
EP0550436A1 (en) 1989-11-06 1993-07-14 Alkermes Controlled Therapeutics, Inc. Protein microspheres and methods of using them
US5183884A (en) 1989-12-01 1993-02-02 United States Of America Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
ATE139258T1 (de) 1990-01-12 1996-06-15 Cell Genesys Inc Erzeugung xenogener antikörper
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5349053A (en) 1990-06-01 1994-09-20 Protein Design Labs, Inc. Chimeric ligand/immunoglobulin molecules and their uses
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DE69123241T2 (de) 1990-12-14 1997-04-17 Cell Genesys Inc Chimärische ketten zur transduktion von rezeptorverbundenen signalwegen
ATE221379T1 (de) 1991-05-01 2002-08-15 Jackson H M Found Military Med Verfahren zur behandlung infektiöser respiratorischer erkrankungen
DE69233408T2 (de) 1991-12-02 2005-09-22 Cambridge Antibody Technology Ltd., Melbourn Herstellung von Antikörpern auf Phagenoberflächen ausgehend von Antikörpersegmentbibliotheken.
ES2341666T3 (es) 1991-12-02 2010-06-24 Medimmune Limited Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos.
EP0746609A4 (en) 1991-12-17 1997-12-17 Genpharm Int NON-HUMAN TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGOUS ANTIBODIES
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
FR2686901A1 (fr) 1992-01-31 1993-08-06 Rhone Poulenc Rorer Sa Nouveaux polypeptides antithrombotiques, leur preparation et compositions pharmaceutiques les contenant.
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5912015A (en) 1992-03-12 1999-06-15 Alkermes Controlled Therapeutics, Inc. Modulated release from biocompatible polymers
US5447851B1 (en) 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
EP0640094A1 (en) 1992-04-24 1995-03-01 The Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
DE69330523D1 (de) 1992-08-21 2001-09-06 Vrije Universiteit Brussel Bru Immunoglobuline ohne leichte ketten
US6765087B1 (en) 1992-08-21 2004-07-20 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
US5958708A (en) 1992-09-25 1999-09-28 Novartis Corporation Reshaped monoclonal antibodies against an immunoglobulin isotype
CA2103323A1 (en) 1992-11-24 1994-05-25 Gregory D. Plowman Her4 human receptor tyrosine kinase
US5934272A (en) 1993-01-29 1999-08-10 Aradigm Corporation Device and method of creating aerosolized mist of respiratory drug
JPH08509612A (ja) 1993-04-26 1996-10-15 ジェンファーム インターナショナル インコーポレイテッド 異種抗体を産生することができるトランスジェニック非ヒト動物
ES2162863T3 (es) 1993-04-29 2002-01-16 Unilever Nv Produccion de anticuerpos o fragmentos (funcionalizados) de los mismos derivados de inmunoglobulinas de cadena pesada de camelidae.
WO1994029351A2 (en) 1993-06-16 1994-12-22 Celltech Limited Antibodies
SE9400088D0 (sv) 1994-01-14 1994-01-14 Kabi Pharmacia Ab Bacterial receptor structures
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US5834252A (en) 1995-04-18 1998-11-10 Glaxo Group Limited End-complementary polymerase reaction
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
MX9700764A (es) 1994-07-29 1997-05-31 Smithkline Beecham Plc Compuestos novedosos.
US6132764A (en) 1994-08-05 2000-10-17 Targesome, Inc. Targeted polymerized liposome diagnostic and treatment agents
CA2207961A1 (en) 1995-01-05 1996-07-11 Robert J. Levy Surface-modified nanoparticles and method of making and using same
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6019968A (en) 1995-04-14 2000-02-01 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
CA2230494A1 (en) 1995-08-31 1997-03-06 Alkermes Controlled Therapeutics Inc. Composition for sustained release of an agent
EP0885002B1 (en) 1996-03-04 2011-05-11 The Penn State Research Foundation Materials and methods for enhancing cellular internalization
JP4046354B2 (ja) 1996-03-18 2008-02-13 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 増大した半減期を有する免疫グロブリン様ドメイン
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US5985309A (en) 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US6056973A (en) 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
EP0954282B1 (en) 1997-01-16 2005-01-19 Massachusetts Institute Of Technology Preparation of particles for inhalation
US6136558A (en) 1997-02-10 2000-10-24 Genentech, Inc. Heregulin variants
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
ATE319745T1 (de) 1997-05-21 2006-03-15 Biovation Ltd Verfahren zur herstellung von nicht-immunogenen proteinen
ES2231991T3 (es) 1997-06-11 2005-05-16 Borean Pharma A/S Modulo de trimerizacion.
EP0985039B1 (en) 1997-06-12 2008-02-20 Novartis International Pharmaceutical Ltd. Artificial antibody polypeptides
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
AU9805398A (en) 1997-10-15 1999-05-03 Children's Medical Center Corporation Novel human egf receptors and use thereof
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
SE512663C2 (sv) 1997-10-23 2000-04-17 Biogram Ab Inkapslingsförfarande för aktiv substans i en bionedbrytbar polymer
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
DK1071700T3 (da) 1998-04-20 2010-06-07 Glycart Biotechnology Ag Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet
AU747231B2 (en) 1998-06-24 2002-05-09 Alkermes, Inc. Large porous particles emitted from an inhaler
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
KR101077001B1 (ko) 1999-01-15 2011-10-26 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
AU3672800A (en) 1999-04-09 2000-11-14 Kyowa Hakko Kogyo Co. Ltd. Method for controlling the activity of immunologically functional molecule
DE19932688B4 (de) 1999-07-13 2009-10-08 Scil Proteins Gmbh Design von Beta-Faltblatt-Proteinen des gamma-II-kristallins antikörperähnlichen
PT1144607E (pt) 1999-07-20 2009-04-22 Morphosys Ag Novos métodos para apresentar (poli)peptídeos/ proteínas em partículas bacteriofágicas através de ligações dissulfureto
CN1371416B (zh) 1999-08-24 2012-10-10 梅达里克斯公司 人ctla-4抗体及其应用
EP2275557A1 (en) 2000-04-12 2011-01-19 Human Genome Sciences, Inc. Albumin fusion proteins
CA2441903C (en) 2000-05-26 2012-07-31 National Research Council Of Canada Single-domain brain-targeting antibody fragments derived from llama antibodies
ES2405944T3 (es) 2000-11-30 2013-06-04 Medarex, Inc. Ácidos nucleicos que codifican las secuencias de inmunoglobulina humana reorganizadas a partir de ratones transcromoscómicos transgénicos zadas
LT3351246T (lt) 2001-02-19 2019-07-10 Novartis Pharma Ag Rapamicino darinys, skirtas kieto naviko, susijusio su nereguliuojama angiogeneze, gydymui
US20040175756A1 (en) 2001-04-26 2004-09-09 Avidia Research Institute Methods for using combinatorial libraries of monomer domains
US20050053973A1 (en) 2001-04-26 2005-03-10 Avidia Research Institute Novel proteins with targeted binding
US20050048512A1 (en) 2001-04-26 2005-03-03 Avidia Research Institute Combinatorial libraries of monomer domains
JP2004532038A (ja) 2001-05-17 2004-10-21 ディヴァーサ コーポレイション 新規抗原結合分子の治療、診断、予防、酵素、産業ならびに農業各分野への応用とそのための新規抗原結合分子の作製とスクリーニングの方法
WO2003002609A2 (en) 2001-06-28 2003-01-09 Domantis Limited Dual-specific ligand and its use
ITMI20011483A1 (it) 2001-07-11 2003-01-11 Res & Innovation Soc Coop A R Uso di composti come antagonisti funzionali ai recettori centrali deicannabinoidi
US7125680B2 (en) 2001-07-27 2006-10-24 The Regents Of The University Of California Methods and materials for characterizing and modulating interaction between heregulin and HER3
EP1283053A1 (en) 2001-08-09 2003-02-12 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibitors of HER3 activity
ATE430580T1 (de) 2001-10-25 2009-05-15 Genentech Inc Glycoprotein-zusammensetzungen
ATE395413T1 (de) 2001-12-03 2008-05-15 Amgen Fremont Inc Antikörperkategorisierung auf der grundlage von bindungseigenschaften
KR100956195B1 (ko) 2002-02-01 2010-05-06 어리어드 파마슈티칼스, 인코포레이티드 인 함유 화합물 및 이의 용도
US7335478B2 (en) 2002-04-18 2008-02-26 Kalobios Pharmaceuticals, Inc. Reactivation-based molecular interaction sensors
US20030157579A1 (en) 2002-02-14 2003-08-21 Kalobios, Inc. Molecular sensors activated by disinhibition
US20040110226A1 (en) 2002-03-01 2004-06-10 Xencor Antibody optimization
AU2003244817B2 (en) 2002-06-28 2010-08-26 Domantis Limited Antigen-binding immunoglobulin single variable domains and dual-specific constructs
JP2006519763A (ja) 2002-11-08 2006-08-31 アブリンクス エン．ヴェー． 治療用ポリペプチドの投与法およびそのためのポリペプチド
AU2003290330A1 (en) 2002-12-27 2004-07-22 Domantis Limited Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
US20050008625A1 (en) 2003-02-13 2005-01-13 Kalobios, Inc. Antibody affinity engineering by serial epitope-guided complementarity replacement
EP1627062A1 (en) 2003-05-14 2006-02-22 Domantis Limited A process for recovering polypeptides that unfold reversibly from a polypeptide repertoire
DE10324447A1 (de) 2003-05-28 2004-12-30 Scil Proteins Gmbh Generierung künstlicher Bindungsproteine auf der Grundlage von Ubiquitin
DE602004017726D1 (de) 2003-06-30 2008-12-24 Domantis Ltd Pegylierte Single-domain-antikörper (dAb)
US7399865B2 (en) 2003-09-15 2008-07-15 Wyeth Protein tyrosine kinase enzyme inhibitors
AU2005207003C1 (en) 2004-01-20 2013-06-13 Humanigen, Inc. Antibody specificity transfer using minimal essential binding determinants
US20060008844A1 (en) 2004-06-17 2006-01-12 Avidia Research Institute c-Met kinase binding proteins
WO2006079372A1 (en) 2005-01-31 2006-08-03 Ablynx N.V. Method for generating variable domain sequences of heavy chain antibodies
GB0503546D0 (en) * 2005-02-21 2005-03-30 Hellenic Pasteur Inst Antibody
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
WO2007030642A2 (en) 2005-09-07 2007-03-15 Medimmune, Inc. Toxin conjugated eph receptor antibodies
MX2008003189A (es) 2005-09-07 2008-03-18 Serono Lab Inhibidores de fosfoinositido 3-cinasa para el tratamiento de endometriosis.
US10155816B2 (en) 2005-11-28 2018-12-18 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
AR056857A1 (es) * 2005-12-30 2007-10-24 U3 Pharma Ag Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
KR20090031897A (ko) 2006-06-12 2009-03-30 리셉터 바이오로직스 인크 전-세포 표면 수용체-특이적 치료제
PT2511301T (pt) * 2006-08-04 2018-03-08 Medimmune Ltd Anticorpos humanos para erbb2
WO2008022746A1 (en) * 2006-08-21 2008-02-28 F. Hoffmann-La Roche Ag Tumor therapy with an anti-vegf antibody
US7825127B2 (en) 2006-12-28 2010-11-02 Takeda Pharmaceutical Company, Limited Method for treating cancer
HRP20131113T1 (hr) 2007-02-16 2014-01-17 Merrimack Pharmaceuticals, Inc. Protutijela protiv erbb3 i njihova uporaba
PL2132573T3 (pl) 2007-03-02 2014-09-30 Genentech Inc Prognozowanie odpowiedzi na inhibitor dimeryzacji HER oparte na niskiej ekspresji HER3
US20080245375A1 (en) 2007-04-05 2008-10-09 Medtronic Vascular, Inc. Benign Prostatic Hyperplasia Treatments
CA2699202C (en) 2007-09-12 2016-09-27 F. Hoffmann-La Roche Ag Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use
TW200932257A (en) 2007-10-16 2009-08-01 Receptor Biologix Inc Compositions comprising optimized Her1 and Her3 multimers and methods of use thereof
US8354528B2 (en) 2007-10-25 2013-01-15 Genentech, Inc. Process for making thienopyrimidine compounds
UY31800A (es) 2008-05-05 2009-11-10 Smithkline Beckman Corp Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb
AU2010242914B2 (en) 2009-04-29 2014-11-13 Trellis Bioscience, Llc Improved antibodies immunoreactive with heregulin-coupled HER3
WO2011022727A2 (en) 2009-08-21 2011-02-24 Merrimack Pharmaceuticals, Inc. Antibodies against the ectodomain of erbb3 and uses thereof
US8654108B2 (en) 2009-09-25 2014-02-18 Sharp Kabushiki Kaisha Liquid crystal display device
CA2777242A1 (en) 2009-10-14 2011-04-21 Merrimack Pharmaceuticals, Inc. Bispecific binding agents targeting igf-1r and erbb3 signalling and uses thereof
NO2719708T3 (me) 2009-11-13 2018-03-24
HRP20160737T1 (hr) 2009-12-22 2016-07-15 Roche Glycart Ag Anti-her3-protutijela i njihove uporabe
JP5981853B2 (ja) 2010-02-18 2016-08-31 ジェネンテック， インコーポレイテッド ニューレグリンアンタゴニスト及び癌の治療におけるそれらの使用
NZ602084A (en) 2010-03-11 2014-07-25 Merrimack Pharmaceuticals Inc Use of erbb3 inhibitors in the treatment of triple negative and basal-like breast cancers
ES2566602T3 (es) 2010-04-09 2016-04-14 Aveo Pharmaceuticals, Inc. Anticuerpos anti-ErbB3
EP2569334A4 (en) 2010-05-13 2014-01-22 Fox Chase Cancer Ct RECOMBINANT-PRODUCED ANTIBODIES FOR THE TARGETING OF ERBB SIGNALING MOLECULES AND METHOD FOR THEIR USE FOR DISEASE DIAGNOSIS AND TREATMENT
AU2011254557B2 (en) 2010-05-20 2015-09-03 Ablynx Nv Biological materials related to HER3
UY33492A (es) 2010-07-09 2012-01-31 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
WO2012019024A2 (en) 2010-08-04 2012-02-09 Immunogen, Inc. Her3-binding molecules and immunoconjugates thereof
CA2815154A1 (en) 2010-08-06 2012-02-09 U3 Pharma Gmbh Use of her3 binding agents in prostate treatment
PH12013500333A1 (en) * 2010-08-20 2013-04-22 Novartis Ag Antibodies for epidermal growth factor receptor 3 (her3)
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
US9155802B2 (en) 2010-11-01 2015-10-13 Symphogen A/S Pan-HER antibody composition
ITRM20100577A1 (it) 2010-11-02 2012-05-03 Takis Srl Immunoterapia contro il recettore erbb-3
UY33707A (es) 2010-11-04 2012-05-31 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
EP2707391B1 (en) 2011-05-13 2017-11-08 Gamamabs Pharma Antibodies against her3
WO2013016714A1 (en) 2011-07-28 2013-01-31 Sea Lane Biotechnologies Sur-binding proteins against erbb3
TW201328706A (zh) * 2011-12-05 2013-07-16 Novartis Ag 表皮生長因子受體３（ｈｅｒ３）之抗體
US20130273029A1 (en) 2011-12-05 2013-10-17 Novartis Ag Antibodies for epidermal growth factor receptor 3 (her3) directed to domain ii of her3

Also Published As

Publication number Publication date
CU24094B1 (es) 2015-04-29
DOP2013000044A (es) 2013-05-31
CA2806637C (en) 2020-08-25
PL2606070T4 (pl) 2017-06-30
CO6680688A2 (es) 2013-05-31
CN103080134A (zh) 2013-05-01
JP6416161B2 (ja) 2018-10-31
EP2606070B1 (en) 2016-12-21
GEP201706605B (en) 2017-01-25
CN105037552B (zh) 2019-03-29
SI2606070T1 (sl) 2017-04-26
GT201300046A (es) 2015-06-02
US10077317B2 (en) 2018-09-18
MA34524B1 (fr) 2013-09-02
US20190194347A1 (en) 2019-06-27
WO2012022814A1 (en) 2012-02-23
JP6771002B2 (ja) 2020-10-21
DK2606070T3 (en) 2017-03-27
HRP20170462T1 (hr) 2017-05-19
JP6057896B2 (ja) 2017-01-11
UA114883C2 (uk) 2017-08-28
CL2013000459A1 (es) 2014-01-31
SMT201700217T1 (it) 2017-05-08
US20170166653A1 (en) 2017-06-15
PT2606070T (pt) 2017-03-31
ES2620255T3 (es) 2017-06-28
US8735551B2 (en) 2014-05-27
AU2011290672B2 (en) 2015-07-09
PE20140230A1 (es) 2014-02-26
CU20130023A7 (es) 2013-05-31
JP6770944B2 (ja) 2020-10-21
AU2011290672A1 (en) 2013-03-21
CY1118761T1 (el) 2017-07-12
CR20130071A (es) 2013-03-13
JP2018090590A (ja) 2018-06-14
EA201300256A1 (ru) 2013-08-30
EA036314B1 (ru) 2020-10-26
PL2606070T3 (pl) 2017-06-30
PH12013500333A1 (en) 2013-04-22
CL2014002750A1 (es) 2015-04-06
CN105037552A (zh) 2015-11-11
CN103080134B (zh) 2015-11-25
LT2606070T (lt) 2017-04-10
EP2606070A1 (en) 2013-06-26
JP2013537546A (ja) 2013-10-03
KR20130108304A (ko) 2013-10-02
RS55930B1 (sr) 2017-09-29
CA2806637A1 (en) 2012-02-23
KR102027011B1 (ko) 2019-09-30
MY162825A (en) 2017-07-31
US20120107306A1 (en) 2012-05-03
NZ607337A (en) 2015-06-26
MX2013002046A (es) 2013-04-03
BR112013004012B1 (pt) 2021-03-23
JP2019001791A (ja) 2019-01-10
IL226712B (en) 2018-10-31
IL261916A (en) 2018-10-31
BR112013004012A2 (pt) 2016-06-28
HUE031855T2 (en) 2017-08-28
SG187908A1 (en) 2013-03-28
NI201300023A (es) 2013-04-15
JP2017019815A (ja) 2017-01-26

Similar Documents

Publication Publication Date Title
ME02637B (me) Antitela za receptor 3 faktora rasta epiderma (her3)
US20220348683A1 (en) Antibody that binds erbb-2 and erbb-3
JP2013537546A5 (me)
US8552157B2 (en) c-Kit antibodies and uses thereof
Merchant et al. Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent
RU2011111746A (ru) Композиции рекомбинантных антител против рецептора эпидермального фактора роста
Ko et al. Combination of novel HER2-targeting antibody 1E11 with trastuzumab shows synergistic antitumor activity in HER2-positive gastric cancer
RU2012151823A (ru) Антитела против рецептора эпидермального фактора роста (egfr) и их применение
WO2019241893A2 (en) Anti-her3 antibody and uses thereof
EP3169708B1 (en) Her3 inhibition in low-grade serous ovarian cancers
Rodems et al. Adaptive responses to antibody based therapy
고봉국 Studies of synergistic antibody combination for treatment of patients with HER2-positive cancer
Gu et al. Identification of Anti-ErbB2 Dual Variable Domain Immunoglobulin (DVD-IgTM) Proteins with Unique
HK40006122B (en) Antibody that binds erbb-2 and erbb-3
HK40006122A (en) Antibody that binds erbb-2 and erbb-3